The vaccine contains a Modified Vaccinia Virus Ankara (MVA) vector expressing a stabilized SARS-CoV-2 spike protein (S).~This will be a phase Ib multi-center study in approximately 60 adults aged 18-64 years.~Part A (N=24 seronegative subjects). Each participant will receive two single injections, 28 days apart.~low dose ≥ 1 x 10e7 IU (N=8)~middle dose ≥ 5 x 10e7 IU (N=8)~high dose ≥ 1 x 10e8 IU (N=8)~Part B (N=36 previously mRNA vaccinated subjects). Each participant will receive a single injection.~low dose ≥ 1 x 10e7 IU (N=12)~middle dose ≥ 5 x 10e7 IU (N=12)~high dose ≥ 1 x 10e8 IU (N=12)~All participants will be followed up for safety until D168.
Multi-center phase Ib study to evaluate the Modified Vaccinia Virus Ankara (MVA) vaccine against SARS-CoV-2 in seronegative (Part A) and previously SARS-CoV-2-vaccinated individuals (Part B).